During rAAV-based gene therapy clinical trials, destruction of transduced cells was shown to result from reactivation of capsid-specific cytotoxic CD8+ lymphocytes which had previously been established following natural infections with wild-type AAV (40). This evidence concerns the gene CD8A and infection.